Quick Order Cart

Cat. No. ARG0585

EDAR Knockout MKN45 Cell Line

  • Product Type:

    Genome-edited Cells

  • Tissue Source:

    Stomach

  • Disease:

    Adenocarcinoma

  • Gene Species:

    Homo sapiens (Human)

The EDAR Knockout MKN45 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human MKN45 gastric adenocarcinoma cell line, providing a robust loss-of-function model for the ectodysplasin A receptor (EDAR). EDAR signaling, mediated by the EDARADD/TRAF6 complex, activates NF-??B and JNK pathways to regulate genes such as CCND1 and BCL2, thereby influencing cell proliferation, survival, and invasive behavior. In MKN45 cells, EDAR disruption impairs these oncogenic pathways, making this model ideal for investigating EDAR??s role in gastric cancer progression. Key applications include dissection of NF-??B and JNK signaling, migration and invasion assays, and screening of EDAR-targeted therapeutic compounds.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    MKN45

    Morphology

    Epithelial-like

    Age

    62 years

    Sex of Donor

    Female

    Gene Name

    EDAR

    Gene Species

    Homo sapiens (Human)

    Gene Identifier

    NCBI Gene ID 10913

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    Daily monitoring confirms that the cells are free from bacterial, yeast, and fungal contamination.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

    Pathogens

    Cells tested negative for HIV-1, HBV, and HCV.

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The EDAR Knockout MKN45 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human MKN45 gastric adenocarcinoma line, offering a stable loss-of-function model for studying ectodysplasin A receptor (EDAR) biology. This ready-to-use live cell product enables researchers to dissect EDAR-dependent signaling without reliance on transient silencing techniques, ensuring consistent genetic ablation in all experimental replicates. MKN45 is a poorly differentiated gastric adenocarcinoma cell line with epithelial morphology and tumorigenic properties, widely employed in gastric cancer research. Its aggressive growth characteristics and genetic background representative of advanced disease make it a suitable host for investigating genes involved in tumor progression and metastasis. EDAR functions as the receptor for ectodysplasin A isoforms, triggering assembly of a signaling complex that includes the adaptor EDARADD and the E3 ligase TRAF6. This complex activates TAK1, which in turn stimulates both the IKK complex for NF-??B activation and the JNK kinase cascade. Downstream, NF-??B and JUN transcription factors regulate expression of genes such as CCND1, BCL2, and MMP9, linking EDAR to cell cycle, survival, and matrix remodeling. Crosstalk with Wnt/??-catenin signaling further extends the receptor??s regulatory influence. In MKN45 cells, CRISPR/Cas9-mediated EDAR disruption eliminates receptor-mediated signal transduction, impairing activation of NF-??B and JNK pathways. This abrogates the transcriptional programs that promote proliferation, suppress apoptosis, and facilitate epithelial-to-mesenchymal transition, thereby attenuating oncogenic properties. The knockout cell line thus provides a clean genetic background to study EDAR??s contribution to gastric cancer aggressiveness and its potential as a therapeutic target. Researchers can employ this model to perform NF-??B luciferase reporter assays, phospho-JNK ELISA, and western blotting for pathway components, alongside flow cytometry for cell cycle and apoptosis analysis. Migration and invasion can be assessed using wound healing or transwell assays. The cell line also enables co-immunoprecipitation studies to explore EDARADD/TRAF6 complex alterations and screens for EDAR-targeted agents. For additional support, please reach out to Ascent Research.
Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)